
Angus Chen
Cancer Reporter at STAT
undignified, unfunny, unaward-winning journalist @STATNews. bylines: @wbur @npr @sciam @wnyc | English:Español:中文 BlueSky: angusrohan signal: angus.08
Articles
-
3 days ago |
statnews.com | Angus Chen
CHICAGO — Tests searching for tumor DNA that’s circulating in the blood are surging in popularity, because they can clue clinicians into what’s happening with a patient’s cancer long before any changes appear on more traditional tools like MRI or CT scans. Some of these ctDNA tests can show if cancer will recur months before any lesions are visible, and others can give information about how a cancer will or is responding to a certain therapy.
-
5 days ago |
statnews.com | Adam Feuerstein |Matthew Herper |Angus Chen
This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here. ASCO ends tomorrow, but alas, dear readers, this newsletter’s run of show is over. At least until next year. Before you digest our parting words, a couple of housekeeping notes:
-
5 days ago |
statnews.com | Angus Chen
CHICAGO — New data on two studies are bolstering hopes that CAR-T therapy, which uses engineered immune T cells to fight cancer, may be able to overcome one of the most difficult to treat cancers of the brain, glioblastoma. The data are very early, involving only a handful of patients, and typical indicators of efficacy in clinical trials like overall survival are not yet available. It will take longer follow up and more patients in larger trials to truly determine efficacy, experts said.
-
6 days ago |
statnews.com | Adam Feuerstein |Matthew Herper |Angus Chen
This is the web version of STAT’s special newsletter from the annual meeting of the American Society of Oncology. For more updates on the latest in cancer news, sign up for our Cancer Briefing newsletter here. We’re going to get to today’s new data in a minute, but first let’s deal with a less serious matter: the marketing of pharmaceutical products via the food attendees need to consume at giant medical meetings. Genentech has been a longtime leader on this front.
-
6 days ago |
flipboard.com | Adam Feuerstein |Matthew Herper |Angus Chen
In the wake of the recent sweeping federal cuts to the US Agency for International Development (USAID) and the US President’s Emergency Plan for AIDS …
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 3K
- Tweets
- 4K
- DMs Open
- No